How a label expansion strategy turned a $200M/year biologic into a multi-billion-dollar opportunity (anonymized case study)

A first-in-class biologic I managed for a rare pediatric leukemia had a U.S. market ceiling of roughly $200M per year. By mapping the target's biology to other hematologic malignancies, solid cancers, and immune-mediated diseases, scoring those indications, and demonstrating efficacy in relevant nonclinical models, we expanded the potential U.S. addressable market into the multi-billions. Potential is not revenue, but it changed every partnering conversation.

What was the starting position, and why was the ceiling about $200M per year?

The asset was a first-in-class biologic directed at a rare pediatric leukemia. The biology was strong, the unmet need was real, and the regulatory path was clear. The commercial problem was arithmetic. Childhood leukemia of every type occurs at about 4.9 cases per 100,000 children and adolescents per year in the United States and accounts for 25.7% of childhood cancers [1]. Our indication was a fraction of that.

A bottom-up market model multiplies incident patients by diagnosis rate, treatment eligibility, achievable share, net price, and duration of therapy. With a few hundred eligible U.S. patients each year, even an orphan-level price produced a ceiling near $200M per year. For scale, NCI estimated that 9,620 children and 5,290 adolescents would be diagnosed with any cancer in 2024 [2].

That population qualifies as an orphan indication, which the Orphan Drug Act defines as a disease affecting fewer than 200,000 persons in the United States [3]. Orphan designation brings tax credits and seven years of exclusivity. It does not bring a market large enough to justify a standalone launch for most partners. That was the gap I set out to close.

How did I map the target's biology to larger disease populations?

I started with the target, not with a list of markets. The questions were where the target is expressed, where it drives disease, and where blocking it should matter. ICH S6(R1) defines a pharmacologically relevant species on the same principle: one in which the test material is active because the receptor or epitope is expressed [4].

That lens surfaced three groups: other hematologic and solid cancer malignancies in which the malignant cells express the same target, and immune-mediated diseases in which the same pathway sustains pathogenic immune cells.

For example, NCI SEER projects 67,790 new leukemia cases and 79,320 new non-Hodgkin lymphoma cases in the United States in 2026, with more than 1.4 million people living with those two diseases [5], [6]. For immune-mediated disease, a 2025 analysis of U.S. electronic health records estimated that 15.4 million Americans, 4.6% of the population, carry at least one of 105 autoimmune diagnoses [7].

Not every patient in those populations is addressable. The relevant subsets express the target, have exhausted standard therapy, and can be identified in a trial. Even after those filters, the eligible population moved from hundreds of patients per year to tens of thousands, with chronic dosing in immune-mediated disease.

How did I prioritize which indications to pursue first?

I scored every candidate indication on five dimensions: unmet need against available therapy, biological rationale, competitive density, trial feasibility, and regulatory path. Each received a one-to-five score with a written justification. The justification mattered more than the number, because investors and advisors challenged the reasoning, not the arithmetic.

Two filters eliminated most candidates. Indications where the target was expressed but not a plausible disease driver scored low on rationale regardless of market size. Crowded indications scored low on competitive density, because a first-in-class mechanism earns its premium where no matched alternative exists.

The framework also forced sequencing. Hematologic and solid cancer malignancies ranked first because they shared the lead indication's trial infrastructure, endpoints, and investigators. Within oncology, hematologic cancers also carry better historical approval odds than solid tumors [8]. Immune-mediated indications became a later priority on the company roadmap.

What nonclinical evidence did we generate, and what does it actually prove?

For each prioritized indication we confirmed target expression in primary patient samples, demonstrated activity against those cells in vitro, and then showed efficacy in a disease-relevant in vivo model comparable with the lead indication. ICH S6(R1) notes that animal models of disease may be useful in selecting clinical indications, which is exactly how we used them [4].

It supported a Fast Track request, a program for drugs for serious conditions with potential to fill an unmet medical need, on which FDA decides within sixty days [9]. FDA granted the designation two months after IND acceptance, and partners received data rather than a hypothesis.

It does not prove the drug works in patients. Nonclinical efficacy is a necessary gate, not a predictor of approval. Across 2011 to 2020, only 7.9% of programs entering Phase 1 reached FDA approval, and hematologic cancers reached approval 7.5% of the time versus 4.6% for solid tumors [8].

How did the target product profile and market model change?

A target product profile (TPP) is a labeling-shaped planning document. FDA's 2007 draft guidance describes it as a summary of drug labeling concepts shared voluntarily with reviewers to focus development discussions [10]. I rebuilt ours so that each indication had its own row for population, line of therapy, endpoint, comparator, and required evidence.

Before approval, new indications enter as protocols under the same IND, and FDA's 2022 expansion cohort guidance permits multiple cohorts in one first-in-human oncology trial to evaluate different populations [11]. After approval, each new indication requires an efficacy supplement approved by FDA before marketing under 21 CFR 601.12 [12].

What changed for investors and partners?

Investors value an early asset as the sum of its indications, each discounted by probability of success and time to market. One indication with a $200M ceiling is a small number however good the science. A portfolio in which one molecule, process, and safety database serve several indications is materially larger after discounting.

Bringing a new medicine to market cost a median of about $1.1 billion in a 2020 analysis of 63 approvals, as corrected by the authors in 2022 [13]. A supplemental indication rides on the existing safety and manufacturing package. From 2017 to 2019, FDA approved 146 supplemental new indications, and only 15.8% were supported by two or more pivotal trials versus 44.0% for original approvals [14].

Partner conversations shifted from whether the indication was worth licensing to which indications they wanted. Several asked about indication-specific or territory-specific structures rather than a single license. The expanded rationale also strengthened later competitive non-dilutive funding applications, though I will not claim it caused any single award.

What does a nonclinical-stage expansion not do?

It does not create revenue, and it does not shorten the clinical path for any indication. Each new indication still needs its own clinical evidence and usually its own pivotal trial. Market potential in the billions describes the opportunity if the drug works; it is not a forecast. Expansion can also dilute focus, so the scoring framework existed to say no to most of the map.

This article is part of the Market Positioning Solutions practice at Hamilton Atlas Group — see the full capability list there.

References

1. National Cancer Institute, SEER Program. Cancer Stat Facts: Childhood Leukemia (Ages 0–19). NCI, 2026.
2. National Cancer Institute. Cancer in Children and Adolescents. NCI, 2024.
3. U.S. Food and Drug Administration. Orphan Drug Act - Relevant Excerpts. FDA, 2018.
4. International Council for Harmonisation. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1). ICH, 2011.
5. National Cancer Institute, SEER Program. Cancer Stat Facts: Leukemia. NCI, 2026.
6. National Cancer Institute, SEER Program. Cancer Stat Facts: Non-Hodgkin Lymphoma. NCI, 2026.
7. Abend AH, He I, et al. Estimation of prevalence of autoimmune diseases in the United States using electronic health record data. J Clin Invest. 2025;135(4):e178722.
8. Biotechnology Innovation Organization, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011-2020. BIO, 2021.
9. U.S. Food and Drug Administration. Fast Track. FDA, 2018.
10. U.S. Food and Drug Administration. Draft Guidance for Industry and Review Staff on Target Product Profile--A Strategic Development Process Tool; Availability. Federal Register 72(61):15141-15142, 2007.
11. U.S. Food and Drug Administration. Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics. FDA, 2022.
12. U.S. Government Publishing Office. 21 CFR 601.12 Changes to an approved application. Code of Federal Regulations, 2024.
13. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853.
14. Dhodapkar M, Zhang AD, Puthumana J, et al. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019. JAMA Netw Open. 2021;4(6):e2113224.